cliexa-Protocols, web-based disease management system is a member of cliexaTM family of products which is a data and algorithm hub. It provides decision support to physicians and other healthcare providers during the treatment process and optimizes treatment methods based on evidence-based knowledge and data.

cliexa-Protocols has started as a pilot program, developed and evolved in early 2014. It was recognized and initiated letter of intents by multiple healthcare provider firms as well as specialty pharma focusing on Hyponatremia and Hep C treatments.

In December 2013, CN4CE Inc. has submitted a 513(g) application for cliexa-Protocols. After reviewed by FDA, FDA confirmed that cliexa-Protocols Disease Management System is a medical device as defined in section 201(h) of the Act.

On May 10, 2016, cliexa-Protocols has received a confirmation from FDA for 513(g) application as cliexa-Protocols will not be enforced any regulatory requirements under applicable provisions of the Section 513(g) Act, including premarket notification, and its implementing regulations, in accordance with the Mobile Medical Applications Guidance.

I am very excited to see Cliexa-IBD as a free application in iTunes store. This is going to provide a very important tool for patients with Crohn’s disease, to assess their disease activity, without any help from others. In addition, this tool gives them an on going monitoring during each and every different treatment. It will help them to remember what has worked and what has not worked in the past. If they are in remission and suddenly the disease becomes active ( as their scores start to rise) this application will allow early intervention in addition it will  remind their healthcare providers,  which of the medications should be chosen first, as the most effective therapy. This is so important in this illness,  where each person has significant variability with activation and remissions. There is no “one medication for all that works in everybody.
It is true that this is a well validated healthcare index that is used by every single drug that is going for FDA approval. Despite of this, it is not widely used in physician offices  because of time constraints.  Cliexa-IBD app will overcome this problem as well.
There are other applications on the market including,  the one which is developed by CCFA utilizing same validated score, CDAI. However in my mind what makes this application superior to others are the two factors that I mentioned above:
1. Ease of use by the patient
2. Ongoing dynamic nature of monitoring the activity of the disease.  utilizing the score on time with the addition of the medications and their effect on the outcome, as soon as the patient starts using them.
 …
So I guess the next step will be to receive the feedback from the patients who are actually using them and forwarding it  to their  healthcare providers. If successful,  this is going to increase the patient adherence to the therapy, thus, facilitating to reach a successful outcome sooner.
Bahri Bilir MD FACP FAASLD
 …
Gastroenterologist at
Rocky Mountain Gastroenterology Denver, Colorado

Newswire Official Press Release

cliexa hosted a booth at Rocky Mountain Gastroenterology’s 15th Annual Pow Wow Conference on Saturday, April 9, 2016. Conference was held at Hyatt Regency at Denver Tech Center, Denver, CO.

The GI Pow Wow is designed to provide a gastroenterology & hepatology update to community primary care providers, surgeons, specialists, as well as medical oncologists & radiologists from throughout Colorado and the surrounding region.

Topics included:

  • Opioid receptors & implications on treating Intestinal Disorders
  • Childhood Obesity & Fatty Liver Treatment
  • IBD Treatment update
  • HCV update
  • Esophageal Cancer Prevention
  • Drug-Induced Liver Disease

At a conference with 400 healthcare industry providers, cliexa had a lot of visitors with lot of questions for cliexa-RA which is in Apple store and cliexa-IBD in early May 2016. Lots of physicians showed interest at scientific disease activity scoring which is tracked with both cliexa-RA and cliexa-IBD dynamically.

Our CTO Nathan Blair, CSO Esra Nutku-Bilir and myself have answered questions from different providers. cliexa-IBD for Inflammatory Bowel Disease is using a survey type disease activity scoring whereas cliexa-RA uses DAS28 joint point calculation.

cliexa-IBD has attracted lots of physicians, who are interested in EMR integration with their current systems which is now part of cliexa’s roadmap.

Here are some photos from the exhibition!

Mehmet Kazgan, CEO.

IMG_4211 IMG_4200

 

One of our partners, Lance Goudzwaard was in the news with //www.histalkpractice.com/.

Read his interview here:

//www.histalkpractice.com/2016/01/21/5-questions-with-lance-goudzwaard-coo-panorama-orthopedics-spine-center/

PR.com Official Press Release

Feb. 11, 2016 – Collaborative Network 4 Clinical Excellence, LLC (CN4CE) has just launched their first mobile chronic disease tracking application, cliexa-RA. cliexa-RA is available for iOS devices in the App Store. It tracks medications, symptoms and disease activity for Rheumatoid Arthritis. The Clinical Excellence Algorithms concept, cliexa™, is the healthcare technology product line for CN4CE which is built on published and recognized scientific quantitative models that translate chronic disease activity into a scoring model.

The Genesis of cliexa™ originated with the idea of applying mobile technology to help optimize chronic disease care. cliexaTM utilizes mobile applications to help patients more accurately track key disease activity indicators used by their physicians to make decisions about their care plan. While CN4CE focuses on Clinical Excellence Networks (CEN) and Disease Management Algorithms/Protocols, cliexa™ interfaces with end users, enabling patients to track daily chronic disease symptoms as well as medications.

cliexa™ is a powerful communication layer for end users to sync with physicians, clinics and other healthcare providers for disease activity tracking and reporting. It also integrates well with cliexa™ web protocols to update Disease Protocols, managed by Medical Directors (CEN) along with the physicians who are experts in their respective specialties.

CN4CE’s Lance Goudzwaard said, “It is hard to remember your RA symptoms and accurately communicate it to physicians during visits.” Dr. Robert Spencer has been integral in developing cliexa-RA,  a tool which allows RA patients to calculate and follow their disease activity using an accepted disease activity measure called the DAS-28. Dr. Spencer stated that, “In today’s demanding medical environment physicians have limited time to gather relevant data, much less calculate an activity index. With an easily used technology application, patients can be instrumental in helping their doctors determine their disease activity, which, in turn, can lead to better informed treatment decisions.”   With cliexa-RA we are offering a free mobile application to achieve this goal. CN4CE Co-Founder and the Scientific Director Dr. Esra Nutku-Bilir said, “cliexa-RA is one step forward in healthcare. The goal has been to design a tool to provide a service based on a need in healthcare… cliexa-RA is designed to gather real life data, which may provide a service tool for patients, physicians, health insurance companies, pharmaceutical companies, with an immense potential to reach out to every aspect of healthcare, today and in the future”.

Bahri Bilir MD FACP FAASLD, could not hide his excitement: “I found this app to be a very important step in realizing the vision of CN4CE, to provide tools to achieve best outcomes in complex chronic illnesses. The simplicity of this app, will allow patients with RA, without anybody’s help, utilize a well accepted and validated scientific tool, to continuously assess and monitor the activity of their illness. I believe that it will improve their adherence to the medications, when they are in remission. In the possibility of a flare, they will be able to see the warning signs, and reach out to their physicians earlier, before they develop deformities or costly ER visits and hospitalizations.”

CN4CE Co-Founder and CEO Mehmet Kazgan added, “Our ultimate vision is to adapt this modular system to other chronic diseases where certain data or clinical indices have been shown to have evidence-based utility in disease and treatment monitoring.”

About CN4CE
CN4CE staff consists of executive healthcare professionals, physicians, scientists and technologists. CN4CE was founded originally in 2011 focusing on Dr. Bahri Bilir’s evidence based disease algorithms concept which has a patent pending status.